Skip to Content
Merck
All Photos(1)

Documents

PHR1224

Supelco

Aminocaproic acid

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

6-Aminocaproic acid, ε-Aminocaproic acid, 6-Aminohexanoic acid, EACA

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
H2N(CH2)5CO2H
CAS Number:
Molecular Weight:
131.17
Beilstein:
906872
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material
pharmaceutical secondary standard

Quality Level

Agency

traceable to Ph. Eur. A0420000
traceable to USP 1021000

API family

aminocaproic acid

CofA

current certificate can be downloaded

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

207-209 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

SMILES string

NCCCCCC(O)=O

InChI

1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)

InChI key

SLXKOJJOQWFEFD-UHFFFAOYSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

Aminocaproic acid is a synthetic inhibitor of fibrinolysis and is utilized for the control of excessive bleeding in patients with amegakaryocytic thrombocytopenia.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Application

Aminocaproic acid may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by fluorimetry and in bulk and injectable forms using colorimetric method.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

Lysine analog. Promotes rapid dissociation of plasmin, thereby inhibiting the activation of plasminogen and subsequent fibrinolysis. Reported to inhibit plasminogen binding to activated platelets. An early report indicated that it inhibits the activation of the first component of the complement system. Binds and inactivates Carboxypeptidase B.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAA9036 in the slot below. This is an example certificate only and may not be the lot that you receive.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The absorption, distribution, and excretion of ?-aminocaproic acid following oral or intravenous administration to man
McNicol GP, et al.
The Journal of Laboratory and Clinical Medicine, 59(1), 15-24 (1962)
Fluorimetric determination of aminocaproic acid in pharmaceutical formulations using a sequential injection analysis system
Pinto PCAG, et al.
Talanta, 68(3), 857-862 (2006)
Aminocaproic acid: use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia
Gardner FH and Helmer RE
JAMA : The Journal of the American Medical Association, 243(1), 35-37 (1980)
Development of Colorimetric Method for the Analysis of Aminocaproic Acid Using DCQ
Shantier SW, et al.
World Journal of Pharmaceutical Research, 4(4), 234-240 (2015)
Brian Hutton et al.
BMJ (Clinical research ed.), 345, e5798-e5798 (2012-09-13)
To estimate the relative risks of death, myocardial infarction, stroke, and renal failure or dysfunction between antifibrinolytics and no treatment following the suspension of aprotinin from the market in 2008 for safety reasons and its recent reintroduction in Europe and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service